Lakefront Biotherapeutics (GLPGF) Cash from Financing Activities (2016 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Cash from Financing Activities for 11 consecutive years, with -$597080.3 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 43.85% year-over-year to -$597080.3 in Q1 2026; TTM through Mar 2026 was -$3.2 million, a 37.14% increase from a year earlier, with the FY2025 full-year figure at -$3.7 million, up 30.61% from the prior year.
• Cash from Financing Activities was -$597080.3 for Q1 2026 at Lakefront Biotherapeutics, down from -$471437.6 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at -$28058.4 in Q1 2022 and troughed at -$5.4 million in Q4 2023.
• A 5-year average of -$1.3 million and a median of -$1.1 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 626.82% in 2023 and jumped 72.5% in 2025, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$1.5 million in 2022, then sank by 254.67% to -$5.4 million in 2023, then soared by 68.15% to -$1.7 million in 2024, then jumped by 72.5% to -$471437.6 in 2025, then retreated by 26.65% to -$597080.3 in 2026.
• The last three Cash from Financing Activities figures came in at -$597080.3 (Q1 2026), -$471437.6 (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.